ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk
Benzinga Newsdesk 11 months ago
News
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's
- Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque
- ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's disease by end of 2025 with planned Q2 2026 interim readout